TY -的T1 -一线卡铂+培美曲塞与培美曲塞维护在艾滋病毒阳性患者先进non-squamous非小细胞肺癌:二期ifct - 1001 CHIVA审判JF -欧洲呼吸杂志》乔和J - 10.1183/13993003.02066 -2019欧元六世- 56 - 2 SP - 1902066 AU Lavole Armelle盟——Greillier Laurent盟——Mazieres朱利安AU -莫内,伊莎贝尔盟——Kiakouama-Maleka Lize盟——Quantin Xavier AU -斯帕诺,让菲利普盟——丽娜,Herve盟——Fraisse Philippe AU - Janicot亨利AU - Audigier-Valette,她非盟- Langlais,亚历山德拉AU -莫林,弗兰克盟——梅金森阿兰盟——Cadranel雅克•A2 - Y1 - 2020/08/01 UR - //www.qdcxjkg.com/content/56/2/1902066.abstract N2 -艾滋病毒感染是一个肺癌试验排除标准。这个多中心II期临床试验旨在评估可行性,有效性和安全性的一线卡铂+培美曲塞(CaP)之后,培美曲塞(P)维护艾滋病毒携带者(感染者)先进non-squamous非小细胞肺癌(NS-NSCLC)。四个周期的帽是紧随其后的是P-maintenance治疗患者的东部合作肿瘤组性能状态≤2。的主要目标是疾病控制的速度12周后(DCR)≥30%。招募的61名感染者中,49(80%)有0 - 1的性能状态,和19例(31%)有脑转移。CD4淋巴细胞计数中位数为418个细胞·µL−1(18 - 1230)中CD4淋巴细胞最低点169.5细胞·µL−1 (1 - 822);48例(80%)患者例病毒学的控制。四冲程是通过诱变以及38例(62%)患者和31例(51%)开始P-maintenance(平均4.1周期(范围-))。为期12周的DCR为50.8% (95% CI 38.3 - -63.4)和部分反应率21.3%。中位无进展生存和总生存期分别为3.5 (95% CI 2.7 - -4.4)和7.6个月(5.7 - -12.8),分别。性能状态0 - 1的患者中位无进展生存时间最长(4.3个月,95%可信区间3.1 - -5.2)和总生存期(11.9个月,95%可信区间6.4 - -14.3)。 During induction, CaP doublet was well tolerated apart from grade 3–4 haematological toxicities (neutropenia 53.8%; thrombocytopenia 35.0%; anaemia 30.0%). Two fatal treatment-related sepses were reported. No opportunistic infections were experienced.In PLHIV with advanced NS-NSCLC, first-line four-cycle CaP induction followed by P-maintenance was effective and reasonably well-tolerated. Further studies should evaluate combination strategies of CaP with immunotherapy in PLHIV.In this first clinical trial dedicated to people living with HIV and advanced non-squamous non-small cell lung cancer, first-line 4-cycle carboplatin plus pemetrexed followed by pemetrexed maintenance chemotherapy was effective and reasonably well-tolerated https://bit.ly/2xAqeEl ER -